Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Efficacy & Safety for LN144 with Pembrolizumab with High Risk Stage IIIb-dResectable Melanoma
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- James Isaacs, MD
- Target Recruit Count
- 12
- Registration Number
- NCT06190249
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
- Conditions
- Recurrent Chronic Lymphocytic LeukemiaRecurrent Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Mantle Cell LymphomaRefractory Transformed Chronic Lymphocytic LeukemiaB-Cell Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRefractory Diffuse Large B-Cell Lymphoma
- Interventions
- Biological: Autologous BAFFR-targeting CAR T CellsDrug: BendamustineProcedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and BiopsyProcedure: Computed TomographyDrug: CyclophosphamideProcedure: EchocardiographyDrug: FludarabineProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 27
- Registration Number
- NCT06191887
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 1080
- Registration Number
- NCT06191744
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Boulder /ID# 261203, Boulder, Colorado, United States
🇺🇸Christiana Care Health Service /ID# 261207, Newark, Delaware, United States
🇺🇸Oncology Hematology Care, Inc - Blue Ash /ID# 261204, Cincinnati, Ohio, United States
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 30
- Registration Number
- NCT06193486
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 100
- Registration Number
- NCT06188676
- Locations
- 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation
Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL
- Conditions
- Interventions
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 150
- Registration Number
- NCT06175702
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: CarboplatinDrug: CisplatinProcedure: Computed TomographyDrug: CyclophosphamideBiological: DinutuximabDrug: DoxorubicinDrug: EtoposideProcedure: FDG-Positron Emission Tomography and Computed Tomography ScanProcedure: Hematopoietic Cell TransplantationDrug: IrinotecanDrug: IsotretinoinProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingDrug: MelphalanRadiation: Radiation TherapyProcedure: Radionuclide ImagingOther: Survey AdministrationDrug: TemozolomideDrug: ThiotepaDrug: TopotecanProcedure: Tumor ResectionDrug: Vincristine
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 478
- Registration Number
- NCT06172296
- Locations
- 🇺🇸
Blank Children's Hospital, Des Moines, Iowa, United States
🇺🇸Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06160362
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 44
- Registration Number
- NCT06155331
- Locations
- 🇪🇬
Hagar Dewidar, Tanta, Elgharbya, Egypt
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 130
- Registration Number
- NCT06153251
- Locations
- 🇪🇸
Clinica Universidad de Navarra, Pamplona, Navarra, Spain
🇫🇷Hôpital Saint-Louis, Paris, France
🇩🇪Universitaetsklinikum Heidelberg, Heidelberg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.